# Tier 5 Enumeration: Diabetes Medications

> **Location in Hierarchy**:
> Tier 1: Medical > Tier 2: Medications > Tier 3: Prescription Medications > Tier 4: Diabetes Medications > **Tier 5: Individual Cards**

---

## Overview

This document enumerates ALL individual Tier 5 cards for Diabetes Medications. Each entry represents ONE SMART card with titratable doses handled within a single card.

**Total Estimated Cards**: ~45 cards

---

## Tier 4: Biguanides

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_DM_BIG_001 | Metformin IR | 500-2550mg daily (divided BID-TID) | T2DM first-line |
| MED_DM_BIG_002 | Metformin ER | 500-2000mg daily | T2DM first-line (better GI tolerance) |

**Subtotal: 2 cards**

---

## Tier 4: Sulfonylureas

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_DM_SU_001 | Glipizide IR | 2.5-40mg daily (divided BID) | T2DM |
| MED_DM_SU_002 | Glipizide ER | 2.5-20mg daily | T2DM |
| MED_DM_SU_003 | Glimepiride | 1-8mg daily | T2DM |
| MED_DM_SU_004 | Glyburide | 1.25-20mg daily (divided BID) | T2DM (less preferred in elderly) |
| MED_DM_SU_005 | Glyburide Micronized | 0.75-12mg daily | T2DM |

**Subtotal: 5 cards**

---

## Tier 4: DPP-4 Inhibitors (Gliptins)

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_DM_DPP4_001 | Sitagliptin (Januvia) | 25-100mg daily | T2DM (adjust for renal) |
| MED_DM_DPP4_002 | Saxagliptin (Onglyza) | 2.5-5mg daily | T2DM |
| MED_DM_DPP4_003 | Linagliptin (Tradjenta) | 5mg daily | T2DM (no renal adjustment) |
| MED_DM_DPP4_004 | Alogliptin (Nesina) | 6.25-25mg daily | T2DM |

**Subtotal: 4 cards**

---

## Tier 4: SGLT2 Inhibitors (Gliflozins)

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_DM_SGLT2_001 | Empagliflozin (Jardiance) | 10-25mg daily | T2DM, HFrEF, CKD |
| MED_DM_SGLT2_002 | Dapagliflozin (Farxiga) | 5-10mg daily | T2DM, HFrEF, HFpEF, CKD |
| MED_DM_SGLT2_003 | Canagliflozin (Invokana) | 100-300mg daily | T2DM, CKD |
| MED_DM_SGLT2_004 | Ertugliflozin (Steglatro) | 5-15mg daily | T2DM |
| MED_DM_SGLT2_005 | Bexagliflozin (Brenzavvy) | 20mg daily | T2DM |

**Subtotal: 5 cards**

---

## Tier 4: Thiazolidinediones (TZDs)

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_DM_TZD_001 | Pioglitazone (Actos) | 15-45mg daily | T2DM, insulin resistance |
| MED_DM_TZD_002 | Rosiglitazone (Avandia) | 4-8mg daily | T2DM (restricted use) |

**Subtotal: 2 cards**

---

## Tier 4: Meglitinides

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_DM_MEG_001 | Repaglinide (Prandin) | 0.5-4mg TID (with meals) | T2DM (flexible meal timing) |
| MED_DM_MEG_002 | Nateglinide (Starlix) | 60-120mg TID (with meals) | T2DM |

**Subtotal: 2 cards**

---

## Tier 4: Alpha-Glucosidase Inhibitors

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_DM_AGI_001 | Acarbose (Precose) | 25-100mg TID (with meals) | T2DM (postprandial glucose) |
| MED_DM_AGI_002 | Miglitol (Glyset) | 25-100mg TID (with meals) | T2DM |

**Subtotal: 2 cards**

---

## Tier 4: GLP-1 Receptor Agonists (Incretin Mimetics)

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_DM_GLP1_001 | Semaglutide (Ozempic) | 0.25-2mg weekly | T2DM, CVD risk reduction |
| MED_DM_GLP1_002 | Semaglutide Oral (Rybelsus) | 3-14mg daily | T2DM (first oral GLP-1) |
| MED_DM_GLP1_003 | Dulaglutide (Trulicity) | 0.75-4.5mg weekly | T2DM, CVD risk reduction |
| MED_DM_GLP1_004 | Liraglutide (Victoza) | 0.6-1.8mg daily | T2DM, CVD risk reduction |
| MED_DM_GLP1_005 | Exenatide (Byetta) | 5-10mcg BID | T2DM |
| MED_DM_GLP1_006 | Exenatide ER (Bydureon) | 2mg weekly | T2DM |
| MED_DM_GLP1_007 | Lixisenatide (Adlyxin) | 10-20mcg daily | T2DM |

**Subtotal: 7 cards**

---

## Tier 4: Dual GIP/GLP-1 Receptor Agonists

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_DM_DUAL_001 | Tirzepatide (Mounjaro) | 2.5-15mg weekly | T2DM, weight management |

**Subtotal: 1 card**

---

## Tier 4: Basal Insulins

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_DM_INS_BAS_001 | Insulin Glargine (Lantus) | 10-100+ units daily | T1DM, T2DM basal coverage |
| MED_DM_INS_BAS_002 | Insulin Glargine U-300 (Toujeo) | 10-100+ units daily | T2DM (concentrated) |
| MED_DM_INS_BAS_003 | Insulin Detemir (Levemir) | 10-100+ units daily/BID | T1DM, T2DM |
| MED_DM_INS_BAS_004 | Insulin Degludec (Tresiba) | 10-100+ units daily | T1DM, T2DM (ultra-long) |
| MED_DM_INS_BAS_005 | NPH Insulin (Humulin N, Novolin N) | 10-100+ units daily/BID | T1DM, T2DM (intermediate) |

**Subtotal: 5 cards**

---

## Tier 4: Rapid-Acting (Bolus) Insulins

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_DM_INS_RAP_001 | Insulin Lispro (Humalog) | Variable (per meal/correction) | T1DM, T2DM mealtime |
| MED_DM_INS_RAP_002 | Insulin Aspart (Novolog) | Variable (per meal/correction) | T1DM, T2DM mealtime |
| MED_DM_INS_RAP_003 | Insulin Glulisine (Apidra) | Variable (per meal/correction) | T1DM, T2DM mealtime |
| MED_DM_INS_RAP_004 | Insulin Lispro-aabc (Lyumjev) | Variable (per meal/correction) | Ultra-rapid mealtime |
| MED_DM_INS_RAP_005 | Insulin Aspart (Fiasp) | Variable (per meal/correction) | Ultra-rapid mealtime |
| MED_DM_INS_RAP_006 | Regular Insulin (Humulin R, Novolin R) | Variable (per meal/correction) | T1DM, T2DM (short-acting) |

**Subtotal: 6 cards**

---

## Tier 4: Premixed Insulins

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_DM_INS_MIX_001 | 70/30 NPH/Regular (Humulin 70/30) | Variable BID | T2DM (simplified regimen) |
| MED_DM_INS_MIX_002 | 75/25 Lispro Mix (Humalog Mix) | Variable BID | T2DM |
| MED_DM_INS_MIX_003 | 70/30 Aspart Mix (Novolog Mix) | Variable BID | T2DM |

**Subtotal: 3 cards**

---

## Tier 4: Concentrated Insulins (Special Cases)

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_DM_INS_CONC_001 | Insulin Lispro U-200 (Humalog U-200) | Variable | T2DM (high insulin needs) |
| MED_DM_INS_CONC_002 | Regular Insulin U-500 (Humulin R U-500) | Variable | Severe insulin resistance |

**Subtotal: 2 cards**

---

## Tier 4: Amylin Analogs

| Card ID | Card Name | Common Doses | Primary Use |
|---------|-----------|--------------|-------------|
| MED_DM_AMYLIN_001 | Pramlintide (Symlin) | 15-120mcg TID (with meals) | T1DM, T2DM (adjunct to insulin) |

**Subtotal: 1 card**

---

## Summary

| Tier 4 Category | Card Count |
|-----------------|------------|
| Biguanides | 2 |
| Sulfonylureas | 5 |
| DPP-4 Inhibitors | 4 |
| SGLT2 Inhibitors | 5 |
| Thiazolidinediones | 2 |
| Meglitinides | 2 |
| Alpha-Glucosidase Inhibitors | 2 |
| GLP-1 Receptor Agonists | 7 |
| Dual GIP/GLP-1 Agonists | 1 |
| Basal Insulins | 5 |
| Rapid-Acting Insulins | 6 |
| Premixed Insulins | 3 |
| Concentrated Insulins | 2 |
| Amylin Analogs | 1 |
| **TOTAL** | **47 cards** |

---

## Card Naming Convention

**Format**: `MED_DM_[SUBCLASS]_[NUMBER]`

**Subclass Abbreviations**:
- `BIG` = Biguanides
- `SU` = Sulfonylureas
- `DPP4` = DPP-4 Inhibitors
- `SGLT2` = SGLT2 Inhibitors
- `TZD` = Thiazolidinediones
- `MEG` = Meglitinides
- `AGI` = Alpha-Glucosidase Inhibitors
- `GLP1` = GLP-1 Receptor Agonists
- `DUAL` = Dual Agonists
- `INS_BAS` = Basal Insulins
- `INS_RAP` = Rapid-Acting Insulins
- `INS_MIX` = Premixed Insulins
- `INS_CONC` = Concentrated Insulins
- `AMYLIN` = Amylin Analogs

**Examples**:
- `MED_DM_BIG_001` = Metformin IR
- `MED_DM_SGLT2_001` = Empagliflozin (Jardiance)
- `MED_DM_INS_BAS_001` = Insulin Glargine (Lantus)

---

## Notes

1. **Titratable doses within single card**: Each card includes all dose tiers (e.g., Metformin card covers 500-2550mg)
2. **Insulin dosing**: Marked as "Variable" because insulin dosing is highly individualized
3. **Brand names included**: Listed in parentheses for common recognition
4. **Off-label uses**: Some SGLT2 inhibitors and GLP-1s now have non-DM indications (HF, CKD, obesity) - primary cards remain here with tags for cross-reference
5. **Combination products**: Fixed-dose combinations (e.g., Janumet = sitagliptin + metformin) NOT enumerated separately; use individual component cards
6. **Not included**: Investigational agents, withdrawn medications

---

## Clinical Pearls for Card Development

When developing individual cards, ensure:

1. **SGLT2i Cards**: Include DKA risk, UTI/genital infection risk, "sick day rules"
2. **GLP-1 Cards**: Include GI side effects timeline, pancreatitis warning, thyroid C-cell tumor risk
3. **Sulfonylurea Cards**: Emphasize hypoglycemia risk, especially in elderly/renal impairment
4. **Insulin Cards**: Include hypoglycemia recognition, storage requirements, injection technique
5. **Metformin Cards**: Include B12 monitoring, lactic acidosis risk factors, contrast hold rules

---

*Version 1.0 | Created: 2024-11-23*
*Source: LIBRARY_TIER_STRUCTURE.md*
